Biocept - Buy the negativity. The revenue doesn't mind. Biocept has the best-in-breed liquid biopsy testing in the Immuno-Oncology space. Market cap is 70 million, but it's going to be several billion in a few years if they don't get bought out first.
Revenue in the second quarter ended 6/30/2016 increased 8 fold to 663,000 from 77,000 last year. This revenue only included half of June for their commerical launch of its PD-L1 protein expression test in mid-June. Frankly, I’m surprised that they didn’t burn through a lot more cash and issue a lot more shares considering their disastrous dilution last year. Their expenses didn’t go up as much as I was expecting either, and they’re sitting on $3.8 million in cash.
Biocept
BIOC Cancer Diagnostics Eliminates Biopsies with Blood TestBlood diagnostic OncoCEE-BR was used by Columbia University College of Physicians and Surgeons in New York City to aid cancer patients' diagnosis. Involved biopsies are no longer required, cancer can be detected with a simple blood test. The chart has strong bullish divergence, has just made a breakout with an initial target around 4 dollars.
